Zentalis Pharmaceuticals, Inc.
ZNTL
$3.86
-$0.17-4.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.97% | 142.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.27% | 9.86% | |||
| Operating Income | -17.27% | -9.86% | |||
| Income Before Tax | -19.63% | -1.32% | |||
| Income Tax Expenses | 15.00% | -72.85% | |||
| Earnings from Continuing Operations | -19.61% | -0.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.61% | -0.39% | |||
| EBIT | -17.27% | -9.86% | |||
| EBITDA | -17.33% | -9.92% | |||
| EPS Basic | -17.85% | -2.38% | |||
| Normalized Basic EPS | -17.84% | -5.31% | |||
| EPS Diluted | -17.85% | -2.38% | |||
| Normalized Diluted EPS | -17.84% | -5.31% | |||
| Average Basic Shares Outstanding | 1.51% | -1.95% | |||
| Average Diluted Shares Outstanding | 1.51% | -1.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||